CDCP1 and lung cancer: To develop potential CDCP1 inhibitors, we performed high‐throughput drug screening with a cell‐based platform and identified a prenylated flavonoid, 8‐isopentenylnaringenin (8PN), as a potential agent to suppress CDCP1 expression and influence lung cancer progression.